| Objective:The purpose of the study is to observe the effect of Bushen Huoxue Lishui Decoction on patients’ quality of life and recurrent cardiovascular events in the vulnerable period of heart failure,and to explore its mechanism,so as to provide objective basis for the promotion of this prescription.Methods:A total of 60 patients who met the diagnostic criteria of acute heart failure and passed the acute phase after receiving standardized western medicine treatment were included.The control group was given the standardized treatment recommended by the guidelines,and the treatment group was given Bushen Huoxue Lishui Decoction on the basis of the control group.Both groups were observed for 12 weeks,and the case would be terminated if the patient had a cardiovascular event(death,rehospitalization due to heart failure,etc.)during the observation.The scores of MLHFQ,KCCQ,TCM syndrome,NYHA,NT-proBNP or BNP,LVEF,LVIDd,rehospitalization and death before and after treatment were observed.The clinical efficacy and safety of the two groups were compared.Results:During the study,1 case in the treatment group and 1 case in the control group were excluded and fell off,and finally 29 cases in the treatment group and the control group were included.The results are as follows:MLHFQ score:After treatment,the scores of both groups were decreased with statistically significant difference(P<0.01).The score of the treatment group was lower than that of the control group,and the difference between the groups was statistically significant(P<0.01).KCCQ score:After treatment,the scores of both groups were increased with statistically significant difference(P<0.01).The score of the treatment group was lower than that of the control group,and the difference between the groups was statistically significant(P<0.01).TCM syndrome score:After treatment,the scores of the two groups were decreased with statistically significant difference(P<0.01).The score of the treatment group was lower than that of the control group,and there was a statistical difference between the groups(P<0.05).The effective rate of the treatment group was 88.0%,the effective rate of the control group was 59.1%,and the effective rate of the treatment group was higher than that of the control group,with a statistical difference(P=0.025).NYHA:After treatment,the effective rate of the treatment group was 96.0%,the effective rate of the control group was 86.4%,and the effective rate of the treatment group was higher than that of the control group,but there was no statistical difference(P=0.243).NT-proBNP or BNP:After treatment,both groups can reduce the level of patients NT-proBNP/BNP,there is a significant statistical difference between the groups(P<0.01);The decrease value of nt-probnp in the treatment group was 1338.72±1329.841,the decrease value of NT-proBNP in the control group was 1239.40±1196.54,the decrease value of BNP in the treatment group was 205.57±142.82,and the decrease value of BNP in the control group was 172.86±189.60,the decrease value in the treatment group was higher than that in the control group,but there was no statistical difference(P>0.05).LVEF:After treatment,the value of LVEF of patients in both groups were significantly increased,with significant statistical difference(P<0.01).The value of LVEF was significantly higher in the treatment group than in the control group(P=0.028).After treatment,the value of LVEF of HFpEF patients in the treatment group was higher than that in the control group with statistical difference(P=0.03).After treatment,the value of LVEF of HFrEF and HFmrEF patients in the treatment group were higher than those in the control group,but there was no significant difference(P=0.487).LVIDd:After treatment,the value of LVIDd was decreased in both groups with statistical difference(P<0.05).The value of LVIDd in the treatment group was lower than that in the control group,but there was no significant difference(P=0.533).Rehospitalization and death events:During the observation period,5 patients were readmitted for cardiovascular events in the control group and 3 patients were readmitted for cardiovascular events in the treatment group,with no statistically significant difference between the two groups(P=0.227).During the observation period,there were 2 deaths due to heart failure in the control group and 1 death due to heart failure in the treatment group,with no statistically significant difference between the two groups(P=0.553).Safety indicators:No drug-related liver and kidney dysfunction or other serious adverse reactions were found in both groups during the treatment.Conclusion:Bushen Huoxue Lishui Decoction combined with western medicine standard treatment for the vulnerable period of heart failure can significantly improve the quality of life,improve heart function NYHA classification,reduce serum B-type natriuretic peptide and improve left ventricular ejection fraction,had a tendency to decrease mortality and recurrence of cardiovascular events. |
PDF Full Text Request